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Abstract Dysfunction of dopaminergic neurotransmis-
sion has been implicated in HIV infection. We showed
previously increased dopamine (DA) levels in CSF of
therapy-naı¨ve HIV patients and an inverse correlation
between CSF DA and CD4 counts in the periphery, sug-
gesting adverse effects of high levels of DA on HIV
infection. In the current study including a total of 167 HIV-
positive and negative donors from Germany and South
Africa (SA), we investigated the mechanistic background
for the increase of CSF DA in HIV individuals. Interest-
ingly, we found that the DAT 10/10-repeat allele is present
more frequently within HIV individuals than in uninfected
subjects. Logistic regression analysis adjusted for gender
and ethnicity showed an odds ratio for HIV infection in
DAT 10/10 allele carriers of 3.93 (95 % CI 1.72–8.96;
p = 0.001, Fishers exact test). 42.6 % HIV-infected
patients harbored the DAT 10/10 allele compared to only
10.5 % uninfected DAT 10/10 carriers in SA (odds ratio
6.31), whereas 68.1 versus 40.9 %, respectively, in Ger-
many (odds ratio 3.08). Subjects homozygous for the
10-repeat allele had higher amounts of CSF DA and
reduced DAT mRNA expression but similar disease
severity compared with those carrying other DAT geno-
types. These intriguing and novel findings show the mutual
interaction between DA and HIV, suggesting caution in the
interpretation of CNS DA alterations in HIV infection
solely as a secondary phenomenon to the virus and open
the door for larger studies investigating consequences of
the DAT functional polymorphism on HIV epidemiology
and progression of disease.
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Introduction
HIV infection causes neurological and psychiatric compli-
cations manifesting in HIV-associated neurocognitive dis-
orders (HAND) despite antiretroviral therapy (Mothobi and
Brew 2012). They occur in various forms and affect med-
ication adherence and quality of life. Research focuses on
host factors that may be implicated in HAND pathogenesis,
the etiology of HAND; however, remains so far unclear.
Disorganization of dopaminergic circuits in HIV infec-
tion has been implicated in the neuropathophysiology of
HIV infection, and has been described extensively in the
reviews of (Koutsilieri et al. 2002; Purohit et al. 2011).
HIV as well as the simian immunodeficiency virus (SIV)
causes apparent reduction in postmortem brain dopamine
(DA) levels (Kumar et al. 2009; Sardar et al. 1996; Scheller
et al. 2005), suggesting that intracellular DA levels are
depleted. An explanation for this may be the dysfunction of
the DA transporter (DAT) known to regulate DA avail-
ability through DA uptake and release. Indeed, decreased
DAT has been found in brains of HIV-associated dementia
patients with positron emission tomography (PET) (Wang
et al. 2004), and HIV proteins have been shown to impair
DAT in animals (Maragos et al. 2002). In contrast,
increased DAT protein has been detected in striatal speci-
mens of subjects with HIV encephalitis (Gelman et al.
2006) and no alterations of DAT were found with single-
photon emission computed tomography (SPECT) in brains
of HIV/treatment-naive patients (Scheller et al. 2010).
However, DA levels were increased in CSF of HIV/treat-
ment-naive patients compared with uninfected subjects
(Scheller et al. 2010), suggesting an altered regulation of
extracellular concentrations of DA.
In the current study, we thought that the increase of CSF
DA may have been due to the genetic constitution of the
subjects and may not have been a direct causal effect of the
virus. We specifically hypothesized that humans carrying a
specific allele of the DAT functional genetic polymorphism
associated with higher availability of DA would (a) have
higher levels of CSF DA (b) be present more frequently
within HIV individuals and (c) show adverse development
of HIV infection compared to those carrying alleles asso-
ciated with reduced DA availability. To assess our
hypothesis we analyzed CSF DA, DAT mRNA expression,
determined DAT genetic polymorphisms in uninfected and
HIV-infected subjects and investigated whether different
ethnicities would influence our assumption. Progression of
disease in the infected groups was based on routine viro-
logical and immunological measures as well as scores in
the HIV dementia scale (HDS), international HIV dementia
scale (IHDS) and global deficit score (GDS). Detailed




A total of 167 people participated in this study: 72 HIV-
infected patients and 22 age-matched controls from Ger-
many as well as 54 HIV-infected patients and 19 controls
from South Africa (SA). All Germans were white. From
SA 88 % were Xhosa (black) and 12 % were colored of
mixed racial ancestry. The study was conducted according
to the guidelines of the declaration of Helsinki. A written
informed consent was obtained from the participants and
investigations were approved by the ethics committees of
the Universities of Du¨sseldorf, Essen, Mu¨nster, Stel-
lenbosch and Cape Town. All German subjects were male.
Both SA uninfected and HIV-infected groups consisted of
63 % females and 37 % males. Participants had education
with a high school diploma in Germany or schooling of
8 years in SA. The virus was transmitted sexually. 68 % of
the German patients received antiretroviral medication
(ARVs), whereas 69 % of the SA subjects were on ARVs.
HIV infection in German participants was most likely
acquired by homosexual transmission (study group consists
of men having sex with men) and in SA by heterosexual
transmission. People presenting with a neurological, psy-
chiatric disorder, history of drug abuse or patients with
opportunistic infections were excluded from this study.
Candidates for HAND were screened in Germany with
HDS (Power et al. 1995; Sakamoto et al. 2013) and in SA
with IHDS (Sacktor et al. 2005) or GDS (Carey et al.
2004). Participants underwent neurological examination
and neuropsychological testing. The neuropsychological
test battery comprised tests for the following domains:
attention (the Mental Alternation Test (MAT) and the
Mental Control Test (MCT)), learning and memory [the
Hopkins Verbal Learning Test (HVLT) and the Brief
Visuospatial Memory Test (BVMT)], psychomotor speed
[Finger tapping (FT) and the Grooved Pegboard Test(GP)],
psychomotor speed [Trail Making Test part A (TMTA),
Color TrailsTest 1(CT1) and Digit Symbol-Coding (DSC)],
executive function [ColorTrails Test 2 (CT2), Stroop
Colour-Word test (SCW), Wisconsin Card-Sorting Test
(WCST), and language (category fluency)]. For GDS, raw
test scores were converted to T scores to control for factors
such as education, gender and ethnicity. Impairment was
classified as having a GDS score of 0.5 or higher. This
cutoff score is known to have a good positive predictor
value for impairment (Carey et al. 2004).
Routine virological and immunological analysis
HIV RNA was extracted in SA with the m2000sp Abbott
Sample Preparation System (Abbott Laboratories, IL,
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USA) and detected with the Abbott m2000 Real-Time
HIV-1 Amplification Reagent Kit. In Germany, HIV RNA
was measured using Abbott RT/m2000 assay (Abbott
Diagnostics, Wiesbaden, Germany). CD4 counts were
determined using FACSs Calibur flow cytometers (Beckton
Dickinson, Franklin Lakes, NJ, USA).
CSF DA quantification
CSF samples for DA detection were supplemented with
phosphoric acid (150 mM, Merck, Darmstadt, Germany)
and stored at -80 C. CSF DA concentration was mea-
sured using a reverse-phase high-pressure liquid chroma-
tography system (Agilent 1100, Waldbronn, Germany) and
detected by electrochemical detection (Koutsilieri et al.
1997). For qualitative and quantitative analyses, we com-
pared retention times and peak heights with those from
commercially available standards (Sigma, St. Louis, MO,
USA).
DAT genotyping
Genomic DNA of participants was purified from peripheral
blood mononuclear cells (PBMC) with the QIAamp DNA
Mini Kit (Qiagen). PBMC were isolated using Histopaque-
1077 gradient centrifugation (Sigma-Aldrich, St. Louis,
MO, USA). The DAT1 30 variable number tandem repeat
(VNTR) polymorphism of SLC6A3 was analyzed with
Taq-polymerase chain reaction (PCR) (New England Bio-
labs, Ipswich, MA, USA) using the forward and reverse
primers TGTAGGGAACGGCCTGAGAG and CTTCC
TGGAGGTCACGGCTCAAAGG (Vandenbergh et al.
1992). PCR products were subjected to 3 % agarose gels
which contained ethidium bromide and analyzed for the
amplified fragment length polymorphisms by comparison
with molecular weight standards.
DAT mRNA expression
RNA of SA patients was isolated from PBMC using the
RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). After
reverse transcription of RNA with the iScript cDNA Syn-
thesis Kit (Bio-Rad, Hercules, CA, USA), cDNA was
analyzed by quantitative real-time PCR (qPCR) using
DyNAmo ColorFlash SYBR Green qPCR Kit (Finnzymes,
Espoo, Finland). The qPCRs were run in duplicates in the
Bio-Rad iCycler (Bio-Rad) using the primers DAT fwd (50-
TCCTGGAACAGCCCCAACT-30) and DAT rev (50-
TGTGGTCCCAAAAGTGTCGTT-30) (Mill et al. 2002).
Amplification was carried out in a final volume of 20 ll
containing 1 ll cDNA, 0.5 lM primer and 0.01 lM fluo-
resceine (Flouresceine Calibrator Dye, Bio-Rad) with 45
cycles of 10 s at 95 C and 5 s 67 C. Gene expression
levels were calculated as relative expression compared to
the housekeeping gene b-actin (QuantiTect Primer assay,
Qiagen) using a standard curve and analyzed with the Bio-
Rad iCycler iQ system program (copies hDAT/copies b-
actin).
Statistical analysis
To assess the influence of the DAT genotype on HIV
infection risk, an unconditional direct logistic regression
model was performed where the odds ratio and 95 %
confidence interval (CI) were computed with an adjustment
for the two potential cofounders’ gender and ethnicity. Due
to the small number of potential cofounders available and
without having an a priori order of importance of those, the
direct regression was preferred over a sequential type.
Statistical differences in genotype and allele frequencies of
the subgroups were analyzed using the Fisher’s exact test.
To compare the means of two groups, we used the unpaired
t test if values were normally distributed and the Mann–
Whitney U test for non-normally distributed values. All
statistical tests were performed with the Software Package
for Social Sciences (SPSS) version 20 and Prism 6 for Mac
OS X. All p values were two-sided, a p value of 0.05 or less
was considered statistically significant.
Results
Patients
German study participants had a mean age of
46.7 ± 10.3 years and SA 36.7 ± 9.3 years (Table 1).
HIV patients in both study groups presented with similar
CD4 counts. Plasma viral load in therapy-naı¨ve patients
was similar between German and SA participants, whereas
SA patients treated with ARVs exhibited a 4.5-fold higher
viral load than those in German patients, suggesting worse
treatment adherence in SA (Table 1). CSF viral load of the
German participants on ARVs was 76-fold less compared
to therapy-naı¨ve patients. 32 % of the German and 23 % of
the SA patients were diagnosed as candidates for cognitive
impairment according to the HDS for German and IHDS or
GDS for SA subjects.
Frequency of DAT alleles
The two ethnic different cohorts exhibited a diverse allele
distribution in the examined DAT polymorphism (Fig. 1a,
b). In Germany, three genotypes were detected including
the 10/10- (62 %), the 9/10- (33 %) and the 9/9-repeat
allele (5 %) (Fig. 1a). This distribution is in accordance
with previous studies in European populations (Kang et al.
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1999). In SA, a greater allele diversity was observed
including 3/7, 3/9, 3/10, 7/9, 9/9, 7/10, 8/10, 9/10, 10/10,
and 10/11 genotypes with the 10/10- and 9/10-repeat
alleles being the most frequent (Fig. 1b).
Correlation of DAT genotypes with HIV infection
Both in Germany and SA, the DAT 10/10-repeat allele was
found at significantly higher frequency in HIV-infected
patients than in uninfected individuals (Fig. 1c, d). 68.1 %
of the HIV-infected patients and 40.9 % of the uninfected
carried the 10/10 allele in Germany. In SA, 42.6 % HIV-
infected and only 10.5 % uninfected carried this allele
(p = 0.0266 for Germany and p = 0.0121 for SA, Fisher’s
exact test) (Fig. 1c, d). The odds ratio for HIV infection
associated with the DAT 10/10 genotype was 3.08 (95 %
CI 1.15–8.23) for the Germans and 6.31 (95 % CI
1.32–30.06) for SA (Fig. 1e). Logistic regression analysis
adjusted for gender and ethnicity in pooled cohorts showed
and odds ratio of 3.93 (95 % CI 1.72–8.96) for the DAT
10/10 allele (p = 0.001), indicating a substantially higher
risk for HIV infection if the DAT 10/10 genotype is present
(Fig. 1e).
Functional changes associated with the DAT 10/10
genotype
Subjects homozygous for the DAT 10-repeat allele
exhibited a significantly higher DA availability compared
to carriers of the second most frequent 9/10-repeat allele
(Fig. 2). CSF DA was measured only from German sub-
jects because CSF from SA was not available. To com-
pensate for this lack and to gain information on the DA
availability in the periphery, we measured the expression
of DAT mRNA in PBMC of SA participants. DAT
expression was similar between HIV-infected and unin-
fected subjects (Fig. 3a) and DAT mRNA did not differ
between people carrying the 10/10- and 9/10-repeat alleles
(Fig. 3b). However, we found a significantly lower mRNA
DAT expression in these subjects who were homozygous
for the 10-repeat allele in contrast to all other genotypes
(Fig. 3c).
No relation between DAT genotype and disease pro-
gression markers such as CD4 count and viral load was
evident (Table 2). Carriers of the DAT 10/10-repeat allele
showed a trend towards higher frequency of neurocogni-
tive impairment (32 %) according to the HDS/IHDS and
GDS compared to 21 % impairment for carriers of the non-
10/10 alleles (Table 2). However, this was not statistically
significant due to the fact that our study was not powered
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Discussion
In this study, we demonstrate for the first time that people
infected with HIV carry significantly more often the DAT
10/10-repeat allele compared to uninfected subjects, indi-
cating that this genotype confers a significant risk factor for
HIV infection. The reason for studying both German and
SA groups was that we initially identified the higher fre-
quency of the DAT 10/10-repeat allele in our German
cohort and we wanted to exclude that this could be a fea-
ture based on homosexuality as the German participants are
men having sex with men. This is why we chose to
investigate further this phenomenon in a completely dif-
ferent setting, with heterosexuals with different ethnicity,
gender and even virus subtype. Indeed our finding on the
frequency of DAT 10/10-repeat allele in HIV-infected
subjects is independent on ethnicity, gender, route of sex-
ual transmission and viral subtype (HIV infections in SA
are predominantly attributed to subtype C (Jacobs et al.
Fig. 1 Distribution of the DAT
polymorphism in German
(GER) and South African (SA)
populations and its association
with the HIV infection.
a Distribution of different DAT
polymorphisms in Germany
with 94 individuals.
b Distribution of different DAT
polymorphisms in SA with 73
individuals. c DAT alleles in
uninfected (n = 22) and HIV-
infected (n = 72) study
participants in Germany
(p = 0.0266, Fisher’s exact
test). d DAT alleles in
uninfected (n = 19) and HIV-
infected (n = 54) study
participants in SA (p = 0.0121,
Fisher’s exact test). e Risk of
acquiring HIV infection
associated with the different
DAT genotypes. Odds ratios for
HIV infection are shown in
diamonds ±95 % confidence
intervals. Polymorphisms
associated with an increased
infection risk are shown in red,
polymorphisms associated with
a reduced infection risk are
shown in green. In addition to a
separate analysis of the odds
ratios for each study group, the
10/10 and 9/10-repeat alleles are
also depicted as pooled data
from the two study groups
Fig. 2 Participants carrying the DAT 10/10-repeat allele have higher
levels of CSF DA compared with those with 9/10-repeat allele. DA
concentration in CSF of German participants with 10/10-repeat allele
(n = 55) and 9/10-repeat allele (n = 28). Box plots show the medians
with upper and lower quartiles. *p = 0.03, significantly different
from 9/10-repeat allele carriers (Mann–Whitney U test for non-
parametric distributed values)
Increases in CSF dopamine in HIV patients 1415
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2009) and in Germany to subtype B (Paraskevis et al.
2009). The independent detection in these different study
populations emphasizes the importance of our findings,
even though the number of screened patients is comparably
low.
One possible explanation for the higher frequency of the
10/10-repeat allele in HIV patients could be that people
carrying this allele have a different behavior including a
risky, impulsive way of life. In this line, the DAT 10/10-
repeat allele has been associated with the attention deficit
hyperactivity disorder (ADHD) (Hawi et al. 2005), a dis-
ease with enhanced impulsivity (Cornish et al. 2005).
Individuals with the highest hyperactivity and impulsivity
scores were found to be homozygous for the DAT
10-repeat allele along with one 7-repeat variant for DRD4
(Roman et al. 2001). The same genetic variants were
associated with reduced inhibition control (Congdon et al.
2008). Interestingly, people with the 10/10-repeat allele
showed more risk taking in a risk-taking task (Mata et al.
2012). In studies with humans, the DAT 10/10-repeat allele
has been associated with changes in DAT availability,
however, without consistent results. Individuals with DAT
10-repeat allele have lower (van de Giessen et al. 2009) or
higher DAT availability (Heinz et al. 2000) than those with
other DAT genotypes. The main role of DAT is to regulate
DA availability (Giros and Caron 1993) by forward and
reverse transport mechanisms that result in changes of
synaptic DA in an opposite mode (Uhl 2003). To check
whether concentrations of DA in HIV-infected subjects
were attributed to the DAT genotype, we measured con-
centrations of DA in CSF which is a useful index of central
DA activity in humans, particularly for the striatum
(Wester et al. 1990). We found that participants with the
10/10-repeat allele had higher levels of CSF DA. This is in
accordance with the only study in the literature to our
knowledge, which reported on DAT genotypes and CSF
DA (Wagner et al. 2007). Those authors, like us here,
reported that individuals with the DAT 10/10-repeat allele
have higher CSF DA levels compared to DAT 9/10 and
DAT 9/9 genotypes in traumatic brain injury patients
(Wagner et al. 2007).
We also found that 10/10-repeat allele carriers had a
significantly lower PBMC DAT expression compared to all
other genotypes. This allows us to assume indirectly on the
alterations in DA availability in the SA participants
because the peripheral PBMC DAT correlates significantly
with the central striatal DAT expression in people with
dopaminergic medication (Pontieri and Colosimo 2010). In
accordance different genotypes of the DAT1 30 VNTR
influence mRNA expression of the DAT both in brain
tissue and lymphocytes, although the expression of DAT in
the periphery is approximately 1,000-fold lower than in the
brain (Mill et al. 2002).
If the DAT 10/10-repeat allele leads to an elevated DA
availability, as we show here, it would be possible that it
causes an exacerbation of CNS HIV infection, as it was
demonstrated previously that SIV neuropathology was
accelerated due to dopaminergic drugs (Czub et al. 2001).
Fig. 3 Participants carrying the DAT 10/10-repeat allele have
reduced levels of PBMC DAT mRNA expression compared with
those with other DAT alleles. a DAT mRNA expression in PBMC of
SA uninfected (n = 17) and HIV-infected subjects (n = 37); b DAT
mRNA expression in PBMC of SA with DAT 10/10 (n = 17) and
9/10-repeat allele (n = 14); c DAT mRNA expression in PBMC of
SA with DAT 10/10 (n = 17) compared with other DAT alleles (3/7,
3/9, 3/10, 7/9, 9/9, 7/10, 8/10, 9/10 and 10/11; n = 37). *p = 0.05,
significantly different from DAT other allele carriers (Mann–Whitney
U test for non-parametric distributed values)
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This issue could not be approached in living people but
neurocognitive scores did not seem to alter in DAT 10/10
carriers with HIV infection. In another study, it was shown
that the dopaminergic drug selegiline, known to increase
DAT expression (Lamensdorf et al. 1999), was well tolerated
by HIV-infected patients with cognitive impairment based
on the neuropsychology scores (Evans et al. 2007; Schifitto
et al. 2007). Another discussion point is that an increase of
DA in the periphery by the DAT 10/10-repeat genotype may
result in an increased infection risk due to the effects of DA
on the immune system per se. It is known that DA may
regulate the initiation and development of immune responses
(Buttarelli et al. 2011). It has been reported that stimulation
of DRD1 receptors, of which the most prominent agonist is
DA itself, inhibits the cytotoxic function of CD8? T cells
(Saha et al. 2001), which play a crucial role in the immune
response towards infections. Individuals with higher DA
levels may, therefore, be more prone towards sexually-
transmitted diseases such as herpes genitalis or syphilis,
which correlate with a 2–5-fold higher infection risk towards
HIV. Besides this indirect effect of DA, DA may also directly
enhance HIV replication. We have shown previously that
DA activates HIV replication in latently infected T cells
in vitro (Scheller et al. 2000), so that individuals with higher
DA levels might have an elevated infection risk towards HIV
due to a faster initial virus replication. As we do not have
information on the virological and immunological status of
the HIV patients in the beginning of their infection, we
cannot know whether the participants with 10/10-repeat
allele had a different initial disease progression. In addition,
as our study was not powered for disease severity, we can
only assume from our results that later on the DAT 10/10-
repeat allele may have no effect on CD4? T cells, viral load
and neurocognitive impairment. This is in agreement with a
previous study which found no effect of DAT genotype on
disease severity and brain function in HIV-infected patients
(Levine et al. 2012) while another group identified that the
DRD3 genetic polymorphism relates with cognitive
impairment in methamphetamine/HIV-infected people
(Gupta et al. 2011).
Taken together, this is the first study to show that
increase in CSF DA levels in HIV-infected subjects is
attributed to the DAT genotype and it is not necessarily a
secondary effect of the virus. In addition, HIV-infected
individuals carry more frequently a genetic variant in a
functional element of the dopaminergic synapse such as
DAT. This could be due to a behavioral trait with a severe
consequence but we cannot rule out the possibility that the
population with HIV has another significant risk factor that
has enriched the frequency of this repeat in these patients.
The strengths of our study are the high odds ratios in both
German and SA groups, as well as the fact that the results
were similar in different ethnicities, were independent on
gender, routes of sexual transmission and viral subtype.
The weakness of the study is that the study sample with
167 participants was modest. However, the sample size
provided enough power to detect statistical significance
between frequency of HIV infection and the DAT variant.
New studies have to be planned with a large sample
number to confirm our data and experimental studies have
to be designed to further elucidate the mechanistic back-
ground of these data.
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